The Glass Lewis Pacira vote recommendation landed firmly in the company’s corner Thursday, with the influential proxy advisory firm telling stockholders to back all three of Pacira BioSciences‘ (Nasdaq: PCRX) director nominees and reject every candidate put forward by activist fund DOMA Perpetual Capital Management ahead of the June 9 annual meeting.
| Item | Detail |
|---|---|
| Annual Meeting Date | June 9, 2026 |
| Pacira Nominees Backed | Christopher Christie, Samit Hirawat MD, Thomas Wiggans |
| DOMA Nominees Rejected | All three (vote AGAINST on white card) |
| Pacira 1-Year TSR (2025) | 37% |
| Cumulative TSR Since 5×30 Launch | 23.8% (Jan. 10, 2025 through Apr. 27, 2026) |
| Pacira Proxy Filing Type | DEFC14A (contested solicitation), filed Apr. 28, 2026 |
Glass Lewis Pacira Vote: Why the Advisory Firm Sided With the Board
Glass Lewis concluded that Pacira’s 5×30 plan, a five-pillar strategy introduced in January 2025 targeting growth through 2030, has already produced competitive shareholder returns over a short window. The firm cited a one-year total stockholder return of 37% for calendar year 2025 and a cumulative return of 23.8% from the strategy’s announcement on January 10, 2025, through April 27, 2026, the last trading day before Pacira filed its definitive contested proxy statement with the SEC.
The advisory firm’s report noted Pacira’s two Phase 2 pipeline candidates, PCRX-201 and PCRX-2002, as evidence the top-line growth story remains in motion. It also pointed to 21 Orange Book-listed patents across two families as a concrete sign the board is actively protecting existing intellectual property, not just managing near-term results.
Glass Lewis described the 5×30 plan as built on “actionable and reasonable goals” and said endorsing the incumbent slate amounts to endorsing CEO Frank Lee’s strategy. Its bottom line: a wait-and-see approach is prudent given the plan’s early stage.
What Glass Lewis Said About DOMA’s Case
The advisory firm was pointed in its skepticism of the challenger. It wrote that DOMA had not presented “sufficiently compelling cause” to disrupt the 5×30 plan at its current stage, and that DOMA’s nominees “do not evidently possess the skills necessary” to execute the strategic overhaul DOMA is proposing.
Glass Lewis also questioned whether DOMA’s position reflects a disciplined review of alternatives or a bias toward an expedited sale of the company. On the specific claim that the board had mishandled risk disclosure, the firm found the critique unfounded, saying Pacira’s language and disclosure levels are in line with industry standards.
DOMA filed its own definitive proxy statement with the SEC on May 12, 2026, nominating three directors and soliciting votes via a white proxy card. According to 13F filing data, DOMA reported 11 holdings with a total portfolio value of approximately $372 million as of Q1 2026, with PCRX listed as its top holding. That concentration means DOMA has a significant stake riding on the outcome, but Glass Lewis argued that stake does not translate into a credible restructuring blueprint.
Pacira’s Proxy Battle Context
Pacira filed its own proxy under the contested-solicitation designation, DEFC14A, on April 28, 2026, a filing type the SEC requires when a company faces a competing slate. The distinction matters: it signals the company anticipated a full fight, not a routine annual meeting.
The 5×30 plan itself, detailed in Pacira’s 2025 Annual Report, is built around expanding its three commercial non-opioid products, EXPAREL, ZILRETTA, and iovera, while advancing the clinical pipeline in musculoskeletal pain. PCRX-201, a locally administered gene therapy for osteoarthritis of the knee, is the most advanced clinical asset and is expected to contribute beyond 2030.
Pacira urged stockholders to vote on the blue proxy card and ignore any white card from DOMA. Goldman Sachs is serving as financial advisor to Pacira; Perkins Coie is legal counsel.
The Glass Lewis Pacira vote recommendation does not guarantee the outcome. ISS, the other major proxy advisory firm, has not yet issued a public recommendation, and its stance could still shift the calculus for institutional holders who defer to both firms before deciding. With the June 9 meeting less than two weeks out, that call is the next number to watch.
